Drug Approval | October 12, 2024
USFDA approves Pfizer’s marstacimab-hncq for treatment of hemophilia A or B
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis